The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 26, 2008
Filed:
Jun. 30, 2005
William R. Ewing, Yardley, PA (US);
Claudio Mapelli, Plainsboro, NJ (US);
Richard B. Sulsky, West Trenton, NJ (US);
Tasir Shamsul Haque, Yardley, PA (US);
Ving G. Lee, Hamilton, NJ (US);
Douglas James Riexinger, Flemington, NJ (US);
Rogelio L. Martinez, Monmouth, NJ (US);
Yeheng Zhu, Stockton, NJ (US);
William R. Ewing, Yardley, PA (US);
Claudio Mapelli, Plainsboro, NJ (US);
Richard B. Sulsky, West Trenton, NJ (US);
Tasir Shamsul Haque, Yardley, PA (US);
Ving G. Lee, Hamilton, NJ (US);
Douglas James Riexinger, Flemington, NJ (US);
Rogelio L. Martinez, Monmouth, NJ (US);
Yeheng Zhu, Stockton, NJ (US);
Bristol-Myers Squibb Company, Princeton, NJ (US);
Abstract
The present invention provides novel human glucagon-like peptide-1 (GLP-1)-receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The peptides of this invention show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes.